Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database

被引：91

作者：

Ito, Kaori ^{[1
]}

Corrigan, Brian ^{[1
]}

Zhao, Qinying ^{[1
]}

French, Jonathan ^{[1
]}

Miller, Raymond ^{[1
]}

Soares, Holly ^{[1
]}

Katz, Elyse ^{[1
]}

Nicholas, Timothy ^{[1
]}

Billing, Bill ^{[1
]}

Anziano, Richard ^{[1
]}

Fullerton, Terence ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, New London, CT USA

来源：

ALZHEIMERS & DEMENTIA | 2011年 / 7卷 / 02期

关键词：

Disease progression model; Natural history; ADAS-cog; MCI; Alzheimer's disease; Age; APOE epsilon 4 genotype; CLINICAL PREDICTORS; RISK-FACTORS; IMPAIRMENT; DEMENTIA; DECLINE; SEX; AGE;

D O I：

10.1016/j.jalz.2010.03.018

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: A mathematical model was developed to describe the longitudinal response in Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) obtained from the Alzheimer's Disease Neuroimaging Methods: The model was fit to the longitudinal ADAS-cog scores from 817 patients. Risk factors (age, apolipoprotein epsilon 4 [APOE epsilon 4] genotype, gentler, family history of AD, years of education) and baseline severity were tested as covariates. Results: Rate of disease progression increased with baseline severity. Age, APOE epsilon 4 genotype, and gender were identified as potential covariates influencing disease progression. The rate of disease progression in patients with mild to moderate AD was estimated as approximately 5.5 points/yr. Conclusions: A disease progression model adequately described the natural decline of ADAS-cog observed in Alzheimer's Disease Neuroimaging Initiative. Baseline severity is an important covariate to predict a curvilinear rate of disease progression in normal elderly, mild cognitive impairment, and AD patients. Age, APOE epsilon 4 genotype, and gender also influence the rate of disease progression. (C) 2011 The Alzheimer's Association. All rights reserved.

引用

页码：151 / 160

页数：10

共 27 条

[11] Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment [J].